glp-1 vs tirzepatide Semaglutide vs retatrutide: the complete three-way comparison Tirzepatide vs Semaglutide - GLP-1

The complete explanation was presented

doi:10.1016/S2468-1253(21)00261-2 46

Japan approved semaglutide 2.4mg for obesity in 2023

Key tips for underwriting applicants with GLP1 use Immediately look for: Evidence of the underlying diagnosis (as seen in medical claims, EHR, APS) Whether the GLP-1 is FDA-approved or off-label for that condition Signs of medication adherence (12 months, regular fills) Get cautious when: A GLP1 appears without any supporting clinical context Fills are intermittent or recently initiated Theres no alignment between the medication and expected companion therapies (e.g., no CPAP with sleep apnea) Be confident when: The diagnosis is clear The drug is first line and clinically appropriate Use has been stable long enough to confer benefit Kyle Schimek, PharmD Kyle Schimek is a board-certified pharmacist and Clinical Services Manager at Milliman IntelliScript

Hossain MA, Kitagaki S, Nakano D, et al